New Enterprise Associates related stories
All articles and analysis
New Enterprise Associates sets up Boston officeNew Enterprise Associates has established an office in Kendall Square in Cambridge to serve its growing portfolio and deal-sourcing work in the greater Boston area. NEA’s current portfolio of Cambridge and Boston area investments includes nearly two dozen healthcare and technology companies and the firm is also a founding partner in The Experiment Fund, a seed-stage fund operating on Harvard’s campus.
NEA opens Boston officeThe new locale will be hub for biotech and life sciences activities
Seed investing in Silicon Valley takes offSeed deals make up 29% of fundings so far in 2013
Hot IPO market fuels follow-on offeringsA number of companies, including LinkedIn and Tableau Software, have carried out large secondary offerings in recent weeks
Hot tech startup Box picks banks for 2014 IPOOffering from VC-backed online storage company could raise about $500 million
- VC-backed Groupon agrees to buy Korea-based Ticket Monster for $260 mln
Ecommerce company Groupon has agreed to acquire Ticket Monster from LivingSocial for $260 million in cash and stock. The deal is expected to close in the first half of 2014. Ticket Monster is a provider of product, local and travel offers in Korea. Groupon is backed by a number of investors that include New Enterprise Associates, Accel Partners, Battery Ventures, Andreessen Horowitz, Greylock Partners, Kleiner Perkins Caulfield & Byers, Maverick Capital, Silver Lake Partners, Technology Crossover Ventures and Maveron.
- VC-backed GlycoMimetics postpones IPO - Fortune
According to Fortune, GlycoMimetics has postponed its IPO that was to have launched on Friday. No reason has been given nor is there a date scheduled for the IPO to debut. The publication reported that the company plans on selling 4 million shares at between $14 and $16 per share. It will trade on the NASDAQ under the ticker symbol "GLYC." Jefferies and Barclays are acting as lead underwriters. Based in Gaithersburg, MD, GlycoMimetics is a biotech company focused on developing glycomimetic drugs. It is backed by New Enterprise Associates, Genzyme Ventures, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures.
- New Enterprise Associates announces a promotion
Global VC firm New Enterprise Associates said Wednesday that it has promoted Ali Behbahani to partner. Dr. Behbahani joined NEA in 2007. He specializes in healthcare investments in the biopharmaceutical and medical device sectors.
- Terrajoule secures Series A
Terrajoule, developers of a flexible technology platform for distributed energy generation, have secured a $11.5 million Series A round of funding. Investors include global venture capital firm New Enterprise Associates; Air Liquide Investments in the future And Demonstration (ALIAD), the capital development company of Air Liquide and individual investors.